Animal model of PCOS provides insight to changes in vascular response. In this animal mode, DHT resulted in a decrease in vasorelaxation of arterial endothelium.
Heavy duty mobility scooters are strong enough to accommodate almost any user. When compared with lighter units, mobility scooters models tend to feature bigger motors, wider bases, and larger tires. While a lighter model may be difficult to maneuver through rougher landscapes, mobility scooter is designed to tackle even the most challenging terrain.An excellent selection of scooters for sale. An extensive scooter accessories section, where find plenty of customization options to help ensure that the model select is a perfect fit.
Side Wheels For Hero Pleasure:
Side Wheel Attachment for Hero Pleasure or Side Wheels For Hero Pleasure or Three wheeler Hero Pleasure for handicapped is product, designed for use with bikes meant for the open road. Instead of shifting with a foot, a rider can drive easily their bike on road using his or her hand. This piece of equipment has been tested at well-known motorcycle tracks. This provides assembly and installation for all products at all facilities.
Side Wheel Attachment For Hero Pleasure to fit the widest array of motorcycles and all-terrain vehicles possible.
Side Wheel Attachment For Hero Pleasure Measurements:
Frame : 38 mm 16 Gauge CR Pipe With Powder Coated
Wheel Hub : Alloys Molded
2 Piece Tyre Size : 3.50 x 10 Inches
2 Piece Tube Size : 3.50 x 10 inches
2 Piece Shocks Up Heavy Duty
4 Piece ball baring
2 Piece pin bush
2 Piece mudguard chrome plated
2 Piece Disk with 4 Hole
Wheel Type: Alloy Wheel
Width: 40" to 48" inch
Carrying Capacity: 100 -150 kg
Side Wheels For Hero Pleasure Features:
Independent Mobility
Minimal Cost
Heavy Duty
International quality standards
Comfort
High level of performance
Carrying Capacity: 100 -150 kg
Sturdy design
Provides excellent balance
Provides excellent support
High durability
Side Wheels For CD Deluxe:
Side Wheel Attachment for CD Deluxe or Side Wheels For CD Deluxe or Three wheeler CD Deluxe for handicapped is product, designed for u
Ergonomic chairs are designed to confirm to a person's physical dimensions, allowing them to sit naturally and comfortably for long periods of time, while reducing the risk of pressure ulcers. Ergonomic system (Intelligent s-shaped ergonomic seating) provides efficient pressure relief by spreading weight over a greater area, at the same time provides stabilization and reduced sliding. With their lightweight frames and seats designed to reduce or prevent pressure points, ergonomic wheelchairs provide a comfortable option for mobility impaired users who have the upper body strength to propel themselves, or a caregiver strong enough to do so.
Karma Ergo Lite 2501 Wheelchair:
The extremely lightweight Ergo Lite 2501 Transport Wheelchair weighs only 8.16 kg. and features an ergonomically-designed seat and backrest, making it one of the most comfortable transport chairs on the market. The folding seat and backrest make the S-Ergo ideal for storage or travel, and the built in AEGIS anti-bacterial cushion provides added comfort and support.
Despite its light weight, the S-Ergo features a 115 kg. weight capacity along with large, 14" flat-free polyurethane rear tires.
Karma Ergo Lite 2501 Wheelchair Features:
Lightest transporter on the market!
Patented S-Style Ergonomic Seat Frame
6061 T-6 Aircraft-grade Aluminum Only 18 lb . (w/ footrests)
Built in Silver Aegis Anti-bacterial Cushion
Fixed Armrests w/Concaved Armpads
Pocket Behind Backrest & Small Carry Pouch on Each Armrest
6" x 1" Polyurethane Front Casters
16" x 17" or 18" x 17" Seat Width
S-Style Ergonomic Seat
14" Rear Polyurethane, High Tread, Flat Free Wheels
3-Stage handle brake: allows light to firm grip for lock
Folding Backrest/ Folding Seat for Transporting in Vehicle or Travel
Fixed Footrests w/ Extra Wide Footplates
Frame Color: Pearl Silver
Weight Capacity of 100 kg
Ergonomic Transporter w/ handle brakes
Karma Ergo Lite 2501 Wheelchair Measurements:
Seat Width 16 inch., 18
Reclining Back Wheelchair( bed cum wheelchair ) which are suitable for indoor as well as outdoor purposes. These wheel chairs are manufactured using high quality material to ensure high strength and durability. Wheelchairs are available in foldable frames and are capable for maximum weight.
Reclining wheelchairs are available in standard folding frames with extended head supports and seat widths up to 24" wide. The recline mechanism is attendant operated with levers much like a bicycle brake lever. The levers operate hydraulic (pump) mechanisms for a smooth adjustment. Using this Recliner Wheelchair mechanism, the chair back can easily and frequently be positioned to any angle.
Reclining Wheelchair 609 GC:
Reclining Wheelchair 609 GC is one of the multipurpose chairs which boast of features like reclining, inbuilt commode, customized armrest and footrest and foldable nature of the chair.
Reclining Wheelchair 609 GC Features:
The wheelchair can be folded within very easily within seconds, making it easier during travels and outings.
The backrest of the chair can be easily reclined, giving the user the freedom to relax by not moving up from the chair.
The footrest can be inclined and adjusted so as to make the user comfortable during reclining or otherwise.
A well paded thigh support is an add-on to the footrest.
The front and rear wheels of the chair are designed and placed in such a way so as to support the reclining of the user, making it a very safe and friendly wheelchair.
The inbuilt commode has its seat just underneath the main seat of the chair; it can be used by just removing the main seat.
The Wheelchair can also be folded from between by just removing the commode and the chair's seat.
This Wheelchair's functionality gives the user total freedom.
Easy to fold and unfold within seconds.
Reclining Wheelchair 609 GC Measurements:
Frame Style : Foldable
Frame Material : MS Chrome Plated
open position wheel to wheel width in : 26" (inch
Serum concentrations of BCAAs are decreased, while the concentrations of the aromatic amino acids (AAAs) phenylalanine and tyrosine are increased, in patients with advanced liver diseases, resulting in a low ratio of BCAAs to AAAs, a ratio called the Fischer ratio
BCAAs were reported to stimulate the production of hepatocyte growth factor
a simplified Fischer ratio, the BCAA to tyrosine ratio (BTR), has been reported useful for predicting serum albumin concentration one year later
BCAA supplementation was shown to delay the progression of CCl4-induced chronic liver injury in a rat model by reducing hepatic apoptosis
BCAAs promoted hepatocyte regeneration in a rat model of hepatectomy
BCAA supplementation for advanced cirrhotic patients improves nutritional status and quality of life
BCAAs activate mTOR and subsequently increase the production of eukaryotic initiation factor 4E-binding protein-1 and ribosomal protein S6 kinase, which upregulate the synthesis of albumin
BCAAs were shown to improve homeostasis model assessment scores for insulin resistance (HOMA-IR) and beta cell function (HOMA-%B) in patients with chronic liver disease, indicating that BCAAs can ameliorate insulin resistance
Several clinical trials have suggested that BCAA supplementation improves the prognosis of cirrhotic patients
A low Fischer ratio has been associated with hepatic encephalopathy
Treatment with BCAAs may therefore have a beneficial effect on patients with hepatic encephalopathy mainly by compensating decreased ratio of BCAAs to AAAs, but not by reducing serum ammonia levels
Two randomized studies also showed that BCAAs did not clearly prevent HE in patients with advanced cirrhosis, although BCAAs prevented the progression of hepatic failure
a systematic review with meta-analyses on the effect of oral BCAAs for the treatment of HE was published[66]. The review has revealed that supplementation of oral BCAAs in cirrhotic patients inhibits the manifestation of HE, especially in patients with overt HE rather than those with minimal HE, but showed no effect on the survival of those patients[66]. Thus, oral administration of BCAAs is the treatment of choice in cirrhotic patients with HE
Study finds that acetyl-11-keto-Beta-boswellic acid (AKBA) reduced growth of pancreatic cancer and metastasis in mouse model. AKBA also inhibits NF-kappaB and induced apoptosis. AKBA is found in Frankinsense.
Karma KM 2500 Small Wheel Wheelchair:
Karma KM 2500 Small Wheel Wheelchair Specifications:
Width 18"
Front/Rear Wheels 6" to 14"
Seat Width 47cm
Seat Depth 40cm
Overall Width 66cm
Overall Collapsed Width 36cm
Armrest Height 21cm
Overall Length 90cm
Seat Height 47cm
Backrest Height 38cm
Overall Height 86cm
Weight 9.2 k.g.
Karma KM 2500 Small Wheel Wheelchair Seat and Back:
AEGIS Microbe Shield Approved by the FDA, EPA, EU, etc., bonded anti-microbial barrier upholstery protects from odor, staining and deterioration from bacteria, fungus and other microorganisms. It is a shield for your health.
Karma KM 2500 Small Wheel Wheelchair Extended Armrest:
By simulating the natural position of arms, the extended armrest design is ergonomic and creates bigger seating space.
An Ultra lightweight wheelchair (9.2 kg) with a compact design for either attendant assisted or self propelling users.
The use of aircraft-grade aluminium alloy and double cross brace provide this model with outstanding strength and durability.
Karma Healthcare KM-2500 Premium Wheelchair is amazingly light and compact transit wheelchair which is ideal for outings and travelers. It folds down to take up virtually no space in the boot of a car and weighs just over 9.2 kg making it easy for anyone to lift into a vehicle.
Backrest folds-down for easy transportation.
Maximum user weight: 100 K.g.
Aluminium frame.
Fixed armrest/fixed footrest.
Foldable frame via double cross bars.
Comfortable & durable upholstery.
Swing-away foot plates.
Puncture proof tyres.
Attendant cable brake.
14" flat-free rear wheels.
Detachable and washable cushion.
One Year Warranty.
It folds down to take up virtually no space in the boot of a car.
This amazingly light and compact transit wheelchair is ideal for outings and travelling.
It comes with detachable and washable cushion.
The wheel chair has attendant cable brake.
It is made from aircraft-grade aluminium alloy fra
O2-O3 triggers tumoricidal immune response after application of a repetitive highly oxidative stimulus by insufflation of a medical O3/O2 gas mixture into the peritoneal cavity in animal model. O3/O2-PP treatment, indicates an enhanced activation of the innate and adaptive arms of the immune system, implicating a role of activated TILs In the anti cancer effects of the O3. Interestingly, COX2 expression was decreased.
Studies have shown that the production of nagalase has a mutual relationship with Gc-MAF level and immunosuppression
It has been demonstrated that serum levels of nagalase are good prognosticators of some types of cancer
The nagalase level in serum correlates with tumor burden and it has been shown that Gc-MAF therapy progresses, nagalase activity decreases
It has been shown that Gc-MAF can inhibit the angiogenesis induced by pro-inflammatory prostaglandin E1
The effect of Gc-MAF on chemotaxis or activation of tumoricidal macrophages is likely the main mechanism against angiogenesis.
Administration of Gc-MAF stimulates immune-cell progenitors for extensive mitogenesis, activates macrophages and produces antibodies. “This indicates that Gc-MAF is a powerful adjuvant for immunization.”
Cancer cell lines do not develop into tumor genes in mouse models after Gc-MAF-primed immunization (29-31) and the effect of Gc-MAF has been approved for macrophage stimulation for angiogenesis, proliferation, migration and metastatic inhibition on tumors induced by MCF-7 human breast cancer cell line
The protocol included: "a high dose of second-generation Gc-MAF (0.5 ml) administered twice a week intramuscularly for a total of 21 injections.”
Yamamoto et al. showed that the administration of Gc-MAF to 16 patients with prostate cancer led to improvements in all patients without recurrence
Inui et al. reported that a 74-year-old man diagnosed with prostate cancer with multiple bone metastases was in complete remission nine months after initiation of GcMAF therapy simultaneously with hyper T/NK cell, high-dose vitamin C and alpha lipoic acid therapy
It has also been approved for non-neoplastic diseases such as autism (41), multiple sclerosis (42, 43), chronic fatigue syndrome (CFS) (40), juvenile osteoporosis (44) and systemic lupus erythematous (45).
Gc-MAF has been verified for use in colon, thyroid (38), lung (39), liver, thymus (36), pancreatic (40), bladder and ovarian cancer and tongue squamous carcinoma
Prostate, breast, colon, liver, stomach, lung (including mesothelioma), kidney, bladder, uterus, ovarian, head/neck and brain cancers, fibrosarcomas and melanomas are the types of cancer tested thus far
weekly administration of 100 ng Gc-MAF to cancer at different stages and types showed curative effects at different follow-up times
this treatment has been suggested for non-anemic patients
Studies have shown that weekly administration of 100 ng Gc-MAF to cancer patients had curative effects on a variety of cancers
Because the half-life of the activated macrophages is approximately one week, it must be administered weekly
In vivo weekly intramuscular administration of Gc-MAF (100 ng) for 16-22 weeks was used to treat patients with breast cancer
individuals harboring different VDR genotypes had different responses to Gc-MAF and that some genotypes were more responsive than others
Administration of Gc-MAF for cancer patients exclusively activates macrophages as an important cell in adaptive immunity
Gc-MAF supports humoral immunity by producing, developing and releasing large quantities of antibodies against cancer. Clinical evidence from a human model of breast cancer patients supports this hypothesis
There is also evidence that confirms the tumoricidal role of Gc-MAF via Fc-receptor mediation
It is likely that the best therapeutic responses will be observed when the nutritional and inflammatory aspects are taken together with stimulation of the immune system
it should be noted that no harmful side effects of Gc-MAF treatment have been reported, even when it was successfully administered to autistic children
The natural activation mechanism of macrophages by Gc-MAF is so natural and it should not have any side effects on humans or animal models even in cell culture
Besides the Gc-MAF efficacy on macrophage activity, it can be a potential anti-angiogenic agent (28) and an inhibitor of the migration of cancerous cells in the absence of macrophages (47).
Activating or modifying natural killer cells, dendritic cells, DC, CTL, INF and IL-2 have all been recommended for cancer immunotherapy
It has been reported that nagalase cannot deglycosylate Gc-MAF as it has specificity for Gc globulin alone
inflammation-derived macrophage activation with the participation of B and T lymphocytes is the main mechanism
macrophages highly-activated by the addition of Gc-MAF can show tumoricidal activity
Previous clinical investigations have confirmed the efficacy of Gc-MAF. In addition to activating existing macrophages, Gc-MAF is a potent mitogenic factor that can stimulate the myeloid progenitor cells to increase systemic macrophage cell counts by 40-fold in four days
it appears more likely that the effectiveness relies on the properties of doxycycline as an inhibitor of tumor cell proliferation and less on its effect as a MMP inhibitor
Our results suggest that doxycycline may be useful not only for the treatment of osteolytic but also for the treatment of osteoblastic bone metastasis
A prominent feature of bone metastasis of breast cancer is the uncoupling of bone remodeling
doxycycline can improve this to some extent by increasing bone formation
the current study clearly demonstrates the benefit of doxycycline when administered from the time of the development of the tumor
In conclusion, doxycycline greatly reduced tumor burden and could also compensate for the increased bone resorption frequently associated with bone metastasis from breast cancer